Published in Science Translational Medicine · View the paper (DOI)
Scientists have developed a personalized platform called TARDIS that accurately detects circulating tumor DNA and signs of residual disease in breast cancer patients. The assay demonstrated a significant improvement in sensitivity, enabling earlier detection of tumors and monitoring patient response to chemotherapy.
Coverage from 2 institutions